B-Cells-in-Cancer-Biology

B CELLS IN CANCER BIOLOGY Recent research has proved B 1 B cell differentiation pathways cells' dual role in cancer immu- notherapy. Tumor-infiltrating B HSC Pro-B cell Pre-B cell Bone Marrow cells can show both protumor Immature B cell and antitumor effects, depend- Plasma cell ing on the tumor microenviron- Short-lived IL-6 ment, phenotypes of B cells present, and antibodies they Plasma cell Mature T2/3 B cell IL-10 produce. Long-lived B cell T1 B cell B cells and plasma cells support BTK IL-4 antitumor immune responses CD45 through several mechanisms. BLNK Plasma cell secretion of tumor cell-specific IgG1 antibodies can Memory B cell Germinal Central B cell mediate ADCC and phagocyto- sis of tumor cells. B cells partici- 2 Anti-tumor and pro-tumor activity of B cells pate in the presentation of tumor-derived antigens to CD4+ Anti-tumor Activity of B cells Pro-tumor Activity of B cells and CD8+ T cells, which can directly present tumor-associat- IFNγ, B cell TAM ed antigens they've captured via IL-12 B cell receptors. And produced CD4+ IL-10 antibodies can support the T cell MHC II TGFβ uptake of tumor antigens by TAMs and dendritic cells. In MHC I IFNγ, TGFβ addition, B cells may promote IL-12 antitumor immunity through the release of cytokines driving Treg cell cytotoxic immune responses. B cells can also directly attack TH1 cell CD8 PD-L1 IL-10, ‘M2-like’ tumor cells using granzyme B CD8+ T cell PD-1 IL-35 macrophage and TRAIL. CD40L CD40 B cells and plasma cells may promote tumor growth through CD4+ T cell several mechanisms. They can release immunosuppressive Effector T cell TGFβ cytokines that promote immuno- IL-10 suppressive phenotypes in myeloid cells, promote Treg cell IFNγ CD8 development, and suppress or misdirect effector T cell respons- ‘M1-like’ CD8+ Tumor-associated PMN-MDSC es. The latter processes could macrophage T cell neutrophil be linked to B cells presenting tumor-derived antigens, which Phagocytosis TCR could be aided by PDL1 expres- MHC II sion. B cells can also produce antibodies that are ineffective at NK cell mediating antitumor responses, such as antibody classes that do ADCC Tumor cells not facilitate antigen presenta- tion or mediate ADCC and tumor B cell cell phagocytosis, or IgG1 antibody specificities that do not Granzyme B elicit an efficient T cell response or innate cell attack. WHAT WE DO: Products: CAR/TCR Vector Systems Creative Biolabs CAR-T Cell Therapy Development Services CAR/TCR Viral Particles Cellular Therapy TCR Modified T Cell Development Services CAR/TCR Jurkat Cells Solutions CAR-B Cell Therapy Development Services Immune Cell Products CAR-NK/Macrophage Development Services Dendritic Cell Vaccine Development Services © 2023 Creative Biolabs All Rights Reserved Email: [email protected]